Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kuros Biosciences | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 1.02B | -89x | -3.26 | CHF 27 | 8.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Relief Therapeutics | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 77M | -1.6x | -0.03 | CHF 6.08 | 6.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ENR Russia Invest | Switzerland | Financial | Investment Banking & Investment Services | CHF 15.45M | 7.7x | 0.07 | CHF 5.50 | -8.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Philip Morris Intl | Switzerland | Consumer Non-Cyclicals | Food & Tobacco | CHF 177.50B | 20.8x | 0.92 | CHF 113 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
3M Co | Switzerland | Consumer Non-Cyclicals | Consumer Goods Conglomerates | CHF 60.42B | 16.1x | 0.08 | CHF 115 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |